` 688428 (InnoCare Pharma Ltd) vs Shanghai Composite Comparison - Alpha Spread

688428
vs
S
Shanghai Composite

Over the past 12 months, InnoCare Pharma Ltd has significantly outperformed Shanghai Composite, delivering a return of +75% compared to the Shanghai Composite's +23% growth.

Stocks Performance
688428 vs Shanghai Composite

Loading
688428
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
688428 vs Shanghai Composite

Loading
688428
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
688428 vs Shanghai Composite

Loading
688428
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
InnoCare Pharma Ltd vs Peers

Shanghai Composite
688428
RYI
AVGR
BROG
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

InnoCare Pharma Ltd
Glance View

Market Cap
20.4B CNY
Industry
Biotechnology

InnoCare Pharma Ltd., a beacon in the bustling world of biotech, epitomizes the fusion of scientific innovation and entrepreneurial vision. Born out of the relentless pursuit to tackle some of the world's most challenging diseases, the company is primarily focused on developing and commercializing novel therapies for cancer and autoimmune diseases. Founded in China, InnoCare leverages its robust research and development network to explore new frontiers in drug discovery, making targeted therapies that aim to meet significant unmet medical needs. The company thrives at the intersection of cutting-edge biotechnology and meticulous clinical trials, bridging the gap between complex scientific data and patient well-being. The business model of InnoCare Pharma revolves around the creation and commercialization of proprietary drug candidates. Revenue streams flow from strategic partnerships, licensing agreements, and ultimately, the sale of its innovative pharmaceutical products. By maintaining a synergistic blend of internal research efforts and external collaborations, InnoCare not only fortifies its pipeline of drug candidates but also expands its global footprint. Their flagship product, often leading the charge from theory to the shelves of hospitals, underscores the company’s commitment to transforming promising scientific research into tangible, life-saving treatments. Through successful navigation of regulatory processes and strategic market entry, InnoCare solidifies its position not just as a pharmaceutical creator, but as a catalyst for hope in combating severe health conditions.

Intrinsic Value
16.43 CNY
Overvaluation 32%
Intrinsic Value
Price
Back to Top